AI Article Synopsis
- Sarcoma is a rare type of cancer with various subtypes, making it challenging to understand its causes and create effective treatments.
- Upcoming research highlights circulating microRNAs (miRNAs) and exosomal miRNAs as potential cancer biomarkers, though their specific roles in sarcoma are not yet well understood.
- In a study focusing on DDLPS, certain miRNAs (miR-1246, -4532, -4454, -619-5p, and -6126) were identified as potential biomarkers, showing high expression in DDLPS cell lines and exosomes, indicating they could aid in early diagnosis or serve as treatment targets.
Article Abstract
Sarcoma is a rare cancer with several subtypes; therefore, our understanding of the pathogenesis of sarcoma is limited, and designing effective treatments is difficult. Circulating microRNAs (miRNAs), including exosomal miRNAs, have attracted attention as biomarkers in cancer. However, the roles of miRNAs and exosomes in sarcoma remain unclear. The present analysis of tissue and serum miRNA expression in osteosarcoma, Ewing's sarcoma and dedifferentiated liposarcoma (DDLPS) identified miR-1246, -4532, -4454, -619-5p and -6126 as biomarkers for DDLPS. These miRNAs were highly expressed in human DDLPS cell lines and exosomes, suggesting that they are secreted from DDLPS tissues. The present results suggested that specific miRNAs may be used as biomarkers for early diagnosis or treatment targets in DDLPS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258628 | PMC |
| http://dx.doi.org/10.3892/ol.2021.12884 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bibliometric analysis of liposarcomas treatment from 2004 to 2023.
J Cancer Res Clin Oncol
January 2025
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital & Institute, Beijing, 100142, P. R. China.
Background: Liposarcomas are mesenchymal malignant tumors characterized by varying degrees of adipocytic differentiation that comprises approximately 20% of soft tissue sarcomas. Despite advancements in this field, there remains a need for a comprehensive understanding of the mechanisms, diagnosis, and treatment of liposarcomas. Currently, there is a lack of bibliometric surveys on the development trajectory of liposarcomas treatment, research hotspots, and author and team collaboration.
View Article and Find Full Text PDFGiant Retroperitoneal Liposarcoma: A Rare Surgical Occurrence.
Cureus
December 2024
General Surgery, Dr. D Y Patil Medical College, Hospital and Research Centre, Dr. D Y Patil Vidyapeeth (Deemed to be University), Pune, IND.
Retroperitoneal liposarcoma is a rare malignancy that arises from adipocytes and can expand significantly before manifesting clinical symptoms. Instances of giant retroperitoneal liposarcoma, defined as tumors larger than 30 cm, are extremely rare, with fewer than 20 reported cases. This case report presents a 68-year-old patient with a significant abdominal mass, ultimately identified and treated as a well-differentiated retroperitoneal liposarcoma.
View Article and Find Full Text PDFNTRK amplification occurs frequently in pan-TRK immunopositive dedifferentiated liposarcomas.
Pathol Oncol Res
January 2025
Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
The () gene family is of rising importance as their fusions are oncogenic, and specific target drugs are available to inhibit the chimera proteins. Pan-TRK antibody, which shows the overexpression of the genes, is a useful tool to detect tumors with or without gene alterations, due to high negative predictive value. Though it is well known that pan-TRK immunopositivity is usually not connected to fusion, the role of other possible genetic alterations is under-researched.
View Article and Find Full Text PDFPurpose: The cancer/testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a promising target in myxoid/round cell liposarcoma (MRCLS).
Methods: In this pilot study, we assessed the adoptive T-cell therapy NY-ESO-1cT letetresgene autoleucel (lete-cel) in patients with human leukocyte antigen (HLA)-A*02:01-, HLA-A*02:05-, and/or HLA-A*02:06-positive advanced/metastatic NY-ESO-1-expressing MRCLS. Patients underwent a reduced-dose (cohort 1) or standard-dose (cohort 2) lymphodepletion regimen (LDR).
Giant Well-Differentiated Liposarcoma of Esophagus Completely Removed by Endoscopic Submucosal Dissection.
Dig Dis Sci
January 2025
Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300# Guangzhou Road, Nanjing, Jiangsu Province, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!